Maria Elena Bottazzi

From Wikipedia, the free encyclopedia
Maria Elena Bottazzi
Maria Elena Bottazzi 2020.jpg
Bottazzi interviewed in 2020

Maria Elena Bottazzi (born in Genova) is an and Italian-born naturalized American [1] microbiologist, currently Associate Dean of the National School of Tropical Medicine at Baylor College of Medicine, as well as Distinguished Professor of Biology at Baylor University, Waco, Texas. She is editor-in-chief of Springer's . She and Peter Hotez led the team that designed COVID-19 vaccine Corbevax.

Early life and education[]

The daughter of a Honduran diplomat, Bottazzi was born in Italy; she moved to Honduras when she was eight.[2][3][4] She studied microbiology and clinical chemistry as an undergraduate at the National Autonomous University of Honduras (1989), then earned a doctorate in molecular immunology and experimental pathology from the University of Florida in 1995.[5] She completed post-doctoral work in cellular biology at the University of Miami (1998) and the University of Pennsylvania (2001).[5]

Career[]

Bottazzi is Associate Dean of the National School of Tropical Medicine at Baylor College of Medicine, and Distinguished Professor of Biology at Baylor University, Waco, Texas.[5]

Along with Peter Hotez, Bottazzi runs the Texas Children's Hospital Center for Vaccine Development.[6] The center develops vaccines for neglected tropical diseases and other emerging and infectious diseases. One of these vaccines was a SARS-CoV vaccine that was ready for human trials in 2016, but at the time the team could find no one interested in funding it.[7] With the onset of the COVID-19 pandemic, Bottazzi and Hotez secured funding to develop Corbevax, a COVID-19 vaccine their group offered without taking a licensing fee for the intellectual property, in hopes of lowering costs of vaccination.[8] It also employs recombinant protein technology, used in vaccines since the 1980s (like the Hepatitis B vaccine),[9] with hopes this would be easier for manufacturers to produce than the newer mRNA technology.[8] In December 2021, Corbevax received emergency use authorization from India, which preordered 300 million doses.[8]

In 2017 Bottazzi received the Orden Gran Cruz Placa de Oro.[10]

She is editor in chief of Springer's .[2]

References[]

  1. ^ https://www.ilsecoloxix.it/italia/2022/01/08/news/maria-elena-bottazzi-il-nostro-nuovo-vaccino-e-un-regalo-al-mondo-adesso-potremo-sconfiggere-la-pandemia-1.41106237/amp/
  2. ^ a b "La científica hondureña en la carrera por crear una vacuna contra el coronavirus en Estados Unidos". BBC News Mundo (in Spanish). Retrieved 2021-12-31.
  3. ^ "Maria Elena Bottazzi | Infectious Diseases Data Observatory". www.iddo.org. Archived from the original on 2021-01-22. Retrieved 2021-01-28.
  4. ^ "Dra. Maria Elena Bottazzi". iddo.org. infectious diseases data observatory. Archived from the original on 22 January 2021. Retrieved 9 April 2021.
  5. ^ a b c "Maria Elena Bottazzi, Ph.D." Baylor College of Medicine. Archived from the original on 26 April 2021. Retrieved 9 April 2021.
  6. ^ "Disease Targets | Texas Children's Hospital". www.texaschildrens.org. Archived from the original on 2021-02-07. Retrieved 2021-04-09.
  7. ^ "Scientists were close to a coronavirus vaccine years ago. Then the money dried up". NBC News. Retrieved 2021-12-31.
  8. ^ a b c Taylor, Adam (December 30, 2021). "A new coronavirus vaccine heading to India was developed by a small team in Texas. It expects nothing in return". The Washington Post. Archived from the original on December 30, 2021. Retrieved December 30, 2021.
  9. ^ "Low-cost and easy-to-make Covid-19 vaccine invented by Texas hospital team wins authorization in India". CNN. 2021-12-28. Retrieved 2021-12-30.{{cite web}}: CS1 maint: url-status (link)
  10. ^ "Congreso otorga su máxima presea a Amado Núñez y María Elena Bottazzi". September 21, 2017. Archived from the original on February 2, 2021. Retrieved January 26, 2021.
Retrieved from ""